Motavizumab, RSV, and subsequent wheezing – Authors' reply

Eric Simões1 hypothesises that the difference in impact on subsequent wheezing between our blinded randomised, double-blind, placebo-controlled trial of monoclonal antibody respiratory syncytial virus (RSV) prevention in healthy, term, Native American infants2 and that of four other RSV prevention s...

Full description

Saved in:
Bibliographic Details
Published in:The Lancet infectious diseases 2016-12, Vol.16 (12), p.1329-1330
Main Authors: O'Brien, Katherine L, Driscoll, Amanda J, Santosham, Mathuram, Hammitt, Laura L, Karron, Ruth A
Format: Article
Language:English
Subjects:
Infectious Disease
Infectious diseases
Low income groups
Pathogens
Population
Prevention
Respiratory syncytial virus
Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Eric Simões1 hypothesises that the difference in impact on subsequent wheezing between our blinded randomised, double-blind, placebo-controlled trial of monoclonal antibody respiratory syncytial virus (RSV) prevention in healthy, term, Native American infants2 and that of four other RSV prevention studies in preterm infants3-6 might relate to differences in underlying wheezing susceptibility in the study populations. [...]the wheezing burden in our Native American study population was substantial.
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(16)30454-6